Like a champion boxer on the ropes, Bristol-Myers Squibb ( BMY 0.84%) finds itself in a challenging position. Specifically, the pharmaceutical giant's shares have declined by a disappointing 11.6% ...

The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.

Citi raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, ...

Bristol-Myers Squibb’s dividend yield is 4.38%. During the last 12 months, it paid $2.48 per share in dividends. Don't Miss: Unlock the hidden potential of commercial real estate — This ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...